Skeletal formula of pargyline
Ball-and-stick model of the pargyline molecule
Systematic (IUPAC) name
Clinical data
CAS Registry Number  Y
ATC code C02 C02
PubChem CID:
DrugBank  N
ChemSpider  Y
Chemical data
Formula C11H13N
Molecular mass 159.23 g/mol

Pargyline (Eutonyl) is an irreversible selective monoamine oxidase (MAO) inhibitor drug (IC50 for MAO-A is 0.01152micromol/L and for MAO-B is 0.00820micromol/L.) [1] [2] It was brought to market in the US and the UK by Abbott in 1963 as "Eutonyl" as an antidepressant, and was one of several other MAO inhibitors brought to market in the 1960s, along with nialamide, isocarboxazid, phenelzine, and tranylcypromine.[3]:146[4]:60[5]

As of 2007 the drug was discontinued[6] and as of 2014 there were no generic versions in the US.[7]

See also


  1. ^ Fisar Z, Hroudová J, Raboch J. (2010). "Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.". Neuro Endocrinol Lett. 31 (5): 645–56.  
  2. ^ Murphy DL, Karoum F, Pickar D, et al. (1998). "Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)". J. Neural Transm. Suppl. 52: 39–48.  
  3. ^ Edward Shorter, A historical dictionary of psychiatry. Oxford University Press, Inc 2005. ISBN 0195176685
  4. ^ William M. Wardell and Louis Lasagna. Regulation Drug Development (Evaluative Studies 21) American Enterprise Institute (1975) ISBN 0844731676
  5. ^ Council on Drugs New Drugs and Developments in Therapeutics: Pargyline Hydrochloride (Eutonyl) JAMA. 1963;184(11):887. doi:10.1001/jama.1963.03700240079013.
  6. ^ W. Steven Pray Interactions Between Nonprescription Products and Psychotropic Medications US Pharmacist. 2007;32(11):12-15.
  7. ^ FDA Eutonyl in the Drugs@FDA Database Accessed July 19, 2014